Six IPOs plan to raise $596 million in the week ahead, with two biotechs targeting billion-dollar-plus valuations.
Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million at a $1.8 billion valuation. Insiders have indicated on $115 million of the IPO. The company is developing antibody drug conjugates, and its pipeline consists of seven candidates targeting hematological malignancies and solid tumors. Its two lead candidates are in pivotal Phase 2 trials, one of which is in collaboration with Genmab (GMAB).
Viela Bio (VIE), which is developing antibodies licensed from AstraZeneca (AZN), plans to raise $150